The estimated Net Worth of Partners, Ltd.Palmetto Part... is at least $6.03 Milion dollars as of 25 June 2018. Partners Part owns over 150,000 units of Xeris Biopharma Inc stock worth over $6,034,774 and over the last 6 years Partners sold XERS stock worth over $0.
Sign up
Partners Part XERS stock SEC Form 4 insiders trading
Partners has made over 1 trades of the Xeris Biopharma Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Partners bought 150,000 units of XERS stock worth $2,250,000 on 25 June 2018.
The largest trade Partners's ever made was buying 150,000 units of Xeris Biopharma Inc stock on 25 June 2018 worth over $2,250,000. On average, Partners trades about 150,000 units every 0 days since 2018. As of 25 June 2018 Partners still owns at least 2,110,061 units of Xeris Biopharma Inc stock.
You can see the complete history of Partners Part stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Partners Part's mailing address?
Partners's mailing address filed with the SEC is 109 N Post Oak Ln, Houston, TX 77024, USA.
Insiders trading at Xeris Biopharma Inc
Over the last 6 years, insiders at Xeris Biopharma Inc have traded over $2,845,230 worth of Xeris Biopharma Inc stock and bought 2,912,235 units worth $31,442,123 . The most active insiders traders include Group, Llc Green Jeremy Red..., James E Deerfield Mgmt L.P.... oraz Garheng Kong. On average, Xeris Biopharma Inc executives and independent directors trade stock every 46 days with the average trade being worth of $197,048. The most recent stock trade was executed by John P. Schmid on 12 August 2024, trading 4,515 units of XERS stock currently worth $10,159.
What does Xeris Biopharma Inc do?
xeris aspires to break through this restraint by developing ultra-low volume, ready-to-use biotherapeutics delivered through patient-friendly injectable devices. products built on our xeriject technologies could potentially ease the pain of injections for hundreds of millions of patients.
What does Xeris Biopharma Inc's logo look like?
Complete history of Partners Part stock trades at Xeris Biopharma Inc
Xeris Biopharma Inc executives and stock owners
Xeris Biopharma Inc executives and other stock owners filed with the SEC include:
-
Paul Edick,
Chairman of the Board, Chief Executive Officer -
John Shannon,
President, Chief Operating Officer -
Paul R. Edick,
Chairman & CEO -
Barry Deutsch,
Chief Financial Officer -
John P. Shannon,
Pres, COO & Director -
Beth Hecht,
Senior Vice President, General Counsel, Corporate Secretary -
Beth P. Hecht J.D.,
Sr. VP, Gen. Counsel, Corp. Sec. & Director -
John Schmid,
Lead Independent Director -
BJ Bormann,
Independent Director -
Marla Persky,
Independent Director -
Jeffrey Sherman,
Independent Director -
Dawn Halkuff,
Independent Director -
Mark Thierer,
Independent Director -
Kenneth Johnson,
Senior Vice President, Clinical Development, Regulatory, Quality Assurance and Medical Affairs -
Steven Prestrelski,
Co-Founder, Chief Scientific Officer -
Dr. Steven J. Prestrelski MBA, Ph.D.,
Co-Founder & Chief Scientific Officer -
Kevin McCulloch,
Sr. VP of Global Operations & Bus. Devel. -
Dr. Kenneth E. Johnson Pharm. D., Pharm.D.,
Sr. VP of Clinical Devel., Regulatory, Quality Assurance & Medical Affairs -
Barry M. Deutsch,
Exec. Officer -
Allison Wey,
Sr. VP of Investor Relations & Corp. Communications -
Steven M. Pieper,
Chief Financial Officer -
Dr. Steven J. Prestrelski,
Co-Founder & Chief Scientific Officer -
Group, Llc Green Jeremy Red...,
-
James E Deerfield Mgmt L.P....,
-
Partners, Ltd.Palmetto Part...,
-
Barbara Jean Anne Bormann K...,
Director -
Jonathan Rigby,
Director -
Kevin Mc Culloch,
See Remarks -
Steven Pieper,
See Remarks -
John Johnson,
Director -
Garheng Kong,
Director -
Ricki Louise Fairley,
Director